Illumina Inc. (ILMN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Illumina ( ILMN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Illumina rose $4.48 (2.6%) to $178.53 on average volume. Throughout the day, 2,349,883 shares of Illumina exchanged hands as compared to its average daily volume of 1,772,200 shares. The stock ranged in a price between $174.23-$180.74 after having opened the day at $175.26 as compared to the previous trading day's close of $174.05. Other companies within the Health Care sector that increased today were: RXi Pharmaceuticals ( RXII), up 28.5%, Celladon ( CLDN), up 25.5%, SunLink Health Systems ( SSY), up 17.1% and Inovio Pharmaceuticals ( INO), up 15.5%.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $22.3 billion and is part of the drugs industry. Shares are up 57.1% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Oculus Innovative ( OCLS), down 11.8%, Five Prime Therapeutics ( FPRX), down 10.1%, Cardiome Pharma Corporation ( CRME), down 5.9% and Mesa Laboratories ( MLAB), down 5.8% , were all laggards within the health care sector with Vertex Pharmaceuticals ( VRTX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Ericsson Rockets After Solid Q1 Following Cevian Push to Accelerate Turnaround

Ericsson Rockets After Solid Q1 Following Cevian Push to Accelerate Turnaround

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved